Surgical Resection vs. Ablative Therapies Through a Laparoscopic Approach for Hepatocellular Carcinoma: a Comparative Study
When compatible with the liver functional reserve, laparoscopic hepatic resection remains the treatment of choice for hepatocellular carcinoma while laparoscopic ablation therapies appear as a promising less invasive alternative. The aim of the study is to compare two homogeneous groups of patients submitted to either hepatic resection or thermoablation for the treatment of single hepatocellular carcinoma (≤ 3 cm).
We enrolled 264 cirrhotic patients out of 905 cases consecutively evaluated for hepatocellular carcinoma. We performed 59 hepatic resections and 205 thermoablations through a laparoscopic approach, and they were then followed for similar follow-up (41.7 ± 31.5 months for laparoscopic hepatic resection vs. 38.7±32.3 for laparoscopic ablation therapy). Outcomes included short- and long-term morbidities, tumoral recurrence, and overall survival.
Short-term morbidity was significantly higher in the resection group (but the two groups had similar rates for severe complications) while, during follow-up, recurrence was more frequent in patients treated with thermoablation, with a clear disadvantage in terms of survival. At multivariate analysis, only the type of surgical treatment was an independent predictor of disease recurrence, while plasmatic alpha-fetoprotein and Hb values, model for end-stage liver disease score, time to recurrence, and the type of surgical treatment were independent predictors of overall survival.
Our data ultimately support some therapeutic advantages for hepatic resection in patients with a single nodule and preserved liver function. However, thermoablation is an adequate alternative in patients with nodules that would require complex surgical resections or imply a poor prognosis that might therefore better tolerate a less invasive procedure.
KeywordsHepatocellular carcinoma Hepatic surgical resection Radiofrequency ablation Liver cirrhosis
Laparoscopic hepatic resection
Laparoscopic ablation therapy
Barcelona Clinic Liver Cancer
Magnetic resonance imaging
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 3.Kutlu O, Chan JA, Aloia TA, Chun YS, Kaseb AO, Passot G, Yamashita S, Vauthey JN, Conrad C. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer 2017; 123: 1817–1827CrossRefPubMedGoogle Scholar
- 4.Santambrogio R, Barabino M, Bruno S, Costa M, Pisani Ceretti A, Angiolini MR, Zuin M, Meloni F, Opocher E. Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients. Surg Endosc 2016; 30: 2103–2113CrossRefPubMedGoogle Scholar
- 8.Tanaka S, Takemura S, Shinkawa H, Nishioka T, Hamano G, Kinoshita M, Ito T, Kubo S. Outcomes of pure laparoscopic versus open hepatic resection for hepatocellular carcinoma in cirrhotic patients: a case-control study with propensity score matching. Eur Surg Res 2015; 55: 291–301CrossRefPubMedGoogle Scholar
- 10.Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, Opocher E, Azoulay D, Cherqui D. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB 2013; 15: 78–84CrossRefPubMedGoogle Scholar
- 24.Kim PN, Choi D, Rhim H, Rha SE, Hong HP, Lee J, Choi J, Kim JW, Seo JW, Lee EJ, Lim HK. Planning ultrasound for percutaneous radiofrequency ablation to treat (<3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility. J Vasc Interv Radiol 2012; 23: 627–634CrossRefPubMedGoogle Scholar
- 25.Kim JE, Kim YS, Rhim H, Lim HK, Lee MW, Choi D, Shin SW, Cho SK. Outcomes of patients with hepatocellular carcinoma referred for percutaneous radiofrequency ablation at a tertiary center: analysis focused on the feasibility with the use of ultrasonography guidance. Eur J Radiol 2011; 79: e80-e84CrossRefPubMedGoogle Scholar
- 29.Vitali GC, Laurent A, Terraz S, Majno P, Buchs NC, Rubbia-Brandt L, Luciani A, Calderaro J, Morel P, Azoulay D, Toso C. Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small (≤3 cm) hepatocellular carcinoma: a case-control study. Surg Endosc 2016; 30: 2301–2307CrossRefPubMedGoogle Scholar
- 35.Shimada S, Kamiyama T, Yokoo H, Orimo T, Wakayama K, Einama T, Kakisaka T, Kamachi H, Taketomi A. Clinicopathological characteristics of hepatocellular carcinoma with microscopic portal venous invasion and the role of anatomical liver resection in these cases. World J Surg 2017; 41: 2087–2094CrossRefPubMedGoogle Scholar
- 38.Fabrega JF, Forner A, Liccioni A, Miquel R, Molina V, Navasa M, Fondevila C, Garcia-Valdecasas JC, Bruix J, Fuster J. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 2016; 63: 839–49CrossRefGoogle Scholar
- 39.Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82–89CrossRefPubMedGoogle Scholar
- 40.Delis SG, Bakoyiannis A, Biliatis I, Athanassiou K, Tassopoulos N, Dervenis C. Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma HPB 2009; 11: 351–357CrossRefPubMedPubMedCentralGoogle Scholar
- 41.The SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 2005; 9: 1207–1215CrossRefGoogle Scholar
- 44.Lee S, Kwon CHD, Kim JM, Joh JW, Paik SW, Kim BW, Wang BW, Wang HJ, Lee KW, Suh KS, Lee SK. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation. Liver Transplant 2014; 20: 1057–1063CrossRefGoogle Scholar
- 46.Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK. Radiofrequency abaltion of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology 2017; 65: 1979–1990CrossRefPubMedGoogle Scholar